<DOC>
	<DOCNO>NCT02273570</DOCNO>
	<brief_summary>Clinical study aim improve anemia management End Stage Renal Disease Patient ( ESRD ) maintenance Hemodialysis evidence Chronic Kidney disease Mineral Bone Disorder ( CKD-MBD )</brief_summary>
	<brief_title>Optimal Anemia Treatment End Stage Renal Disease ( ERSD )</brief_title>
	<detailed_description>Anemia one worrisome complication Chronic Kidney Disease ( CKD ) . Numerous prospective study repeatedly document increase risk morbidity mortality associate low level hemoglobin ( Hb ) . Hence international guideline patient care suggest use Erythropoietin Stimulating Agents ( ESA ) , iron , folates supplementation anemia correction . However , recent randomize control trial ( RCT ) demonstrate hemoglobin correction normal level increase risk major cardiovascular ( CV ) event . Though , reason still unclear , cumulative ESA dose may least partly explain finding suggest limit ESA minimal dose allow achieve suggest Hb target ESRD patient . Among factor , CKD-MBD repeatedly associate poor severe anemia high dose ESA . However , late Kidney Disease : Improving Global Outcomes ( KDIGO ) guideline CKD-MBD management suggest high reference target intact parathyroid hormone ( iPTH ) ( 2-9 fold upper level normal range ) compare National Kidney Foundation ( NKF ) guideline publish 2003 ( 150-300 pg/ml ) . A observational study suggest linear inverse association intact iPTH ESA dose even iPTH value within iPTH target level propose KDIGO work group . Similarly , large body evidence support notion high iPTH faster CV system deterioration ESRD . Aim study test whether tight iPTH control achieve iPTH level lower 300 pg/ml v iPTH level 300-540 pg/ml associate ESA dose reduction slow CV system deterioration ESRD patient receive dialysis . STUDY DESIGN Pilot , single center , open label blind end point ( PROBE-Prospective Randomized Open Blinded End-Point ) aim improve patient care . Eligible patient randomize ( 1:1 ) either : ( A ) Control group : standard care . The iPTH target group 300-540 pg/ml ( B ) Optimal CKD-MBD control : group iPTH target is150-300 pg/ml achieve therapeutic algorithm . TREATMENTS All patient randomize ( 1:1 ) either : ( A ) Control group : standard care . The iPTH target group 300-540 pg/ml . ( B ) Optimal CKD-MBD control : : group iPTH target 150-300 pg/ml achieve therapeutic algorithm : I. iPTH control : order achieve iPTH target ( 150-300 pg/ml ) , patient receive 400 IU/day vitamin-25-OH-D ( 25OHD ) flexible dose active vitamin D available Italy ( calcitriol paricalcitol- '' Zemplar® '' ) maximum dose 6 mcg/week paricalcitol ( `` Zemplar® '' ) equivalent ( see exist conversion table ) . Patients also receive flexible dose cinacalcet ( `` Mimpara® '' ) maximum dose 90 mg/day . II . Phosphorous control : patient need achieve serum phosphorous level lower 5.5 mg/dl . All available phosphate binder allow [ sevelamer ( `` Renvela® '' ) , calcium carbonate , calcium acetate ( `` Phoslo® '' ) , calcium acetate/magnesium carbonate ( `` Osvaren® '' ) , lanthanum carbonate `` Foznol® '' ) . A rescue therapy aluminum ( `` Maalox® '' ) allow 30 day . III . Serum calcium control : suggest target less 9.5 mg/dl . In case serum calcium great 9.5 mg/dl calcium vitamin D dose lower order low risk vascular calcification deposition progression</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>INCLUSION CRITERIA . Men woman Age &gt; 18 year Maintenance dialysis via ArteroVenous fistula ESA use iPTH 300600 pg/ml Hb 10.011.5 Kt/V greater/equal 1.2 Signed inform consent prior initiation study EXCLUSION CRITERIA : None .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hyperparathyroidism , Secondary</keyword>
	<keyword>Anemia</keyword>
	<keyword>Vascular Stiffness</keyword>
	<keyword>Vascular Calcification</keyword>
</DOC>